好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Area Deprivation Index and Progression to Dementia
Behavioral and Cognitive Neurology
S2 - Behavioral Neurology (2:12 PM-2:24 PM)
007

To investigate the association of the area deprivation index (ADI), as assigned at the census block group-level, with progression to dementia in cognitively unimpaired at baseline participants (≥50 years old) of the population-based Mayo Clinic Study of Aging (MCSA).

A limited number of studies support that neighborhood deprivation may contribute to the risk for cognitive impairment, even independently of individual-level socioeconomic measures and other established dementia risk factors.

ADI is a novel, validated, composite measure of neighborhood socioeconomic disadvantage that uses 17 census measures capturing education, employment, income, poverty, and housing characteristics; the census block group (i.e., the closest approximation to a "neighborhood") was the geographic unit of construction. ADI is publicly available (Neighborhood Atlas®, University of Wisconsin, School of Medicine and Public Health). Higher ADI scores indicate greater neighborhood socioeconomic deprivation. MCSA is an age/sex stratified random sample of Olmsted County (MN) residents. The study population consisted of 4,118 participants, with available ADI ranking values relative to the state for 2015 and at least one visit in 2008 – 2018. Cox proportional hazards models were fit to assess progression to dementia, adjusting for sex, education, and apolipoprotein E ε4 allele status, using age as the time scale. 

Participants' mean age (standard deviation (SD)) was 72.0 (10.5) years, and 49.5% were males. 293 participants progressed to dementia during a mean (SD) follow-up of 4.7 (3.4) years. Living in the 20% most (vs. 20% least) socioeconomically disadvantaged neighborhoods relative to the state was associated with a higher risk for progression to dementia (HR=1.56, 95%CI (1.031-2.365), p=0.035).
Census block group-level neighborhood disadvantage was associated with increased risk for progression to dementia, even in a well-resourced region, such as Olmsted County, MN.  Continued research is needed to understand the potential association pathways involved, which are expected to be very intricate.
Authors/Disclosures
Maria Vassilaki, MD, PhD (Mayo Clinic, Department of Quantitative Health Sciences)
PRESENTER 		Dr. Vassilaki has stock in Abbott Laboratories. Dr. Vassilaki has stock in Johnson and Johnson. Dr. Vassilaki has stock in Medtronic. Dr. Vassilaki has stock in Amgen. Dr. Vassilaki has stock in AbbVie. Dr. Vassilaki has stock in Merck. The institution of Dr. Vassilaki has received research support from NIH. The institution of Dr. Vassilaki has received research support from European Union/ St. Anne's University Hospital Brno, Czech Republic. The institution of an immediate family member of Dr. Vassilaki has received research support from Avobis Bio, LLC.
Jeremiah Aakre, MPH Mr. Aakre has nothing to disclose.
Anna Castillo Anna Castillo has nothing to disclose.
No disclosure on file
No disclosure on file
Walter Kremers The institution of Walter Kremers has received research support from NIH. The institution of an immediate family member of Walter Kremers has received research support from NIH.
Michelle M. Mielke, PhD (Wake Forest University School of Medicine) Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LabCorp. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens Healthineers. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunbird Bio. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk.
Yonas E. Geda, MD (Barrow Neurological Institute) The institution of Dr. Geda has received research support from NIH.
Mary M. Machulda, PhD (Mayo Clinic) The institution of Dr. Machulda has received research support from NIH.
Rabe' Alhurani, MBBS (Loyola University Medical Center) Dr. Alhurani has nothing to disclose.
Jonathan Graff-Radford, MD, FAAN Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. Dr. Graff-Radford has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics.
Prashanthi Vemuri, PhD (Mayo Clinic) The institution of Dr. Vemuri has received research support from NIH.
Val J. Lowe, MD (Mayo Clinic) Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals.
Clifford R. Jack, Jr., MD (Mayo Clinic) The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.
David S. Knopman, MD, FAAN (Mayo Clinic) Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.